1093403-33-8 | 4-Methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98+%	in stock	$15.00	$11.00
5mg	98+%	in stock	$38.00	$27.00
10mg	98+%	in stock	$57.00	$40.00
50mg	98+%	in stock	$150.00	$105.00
100mg	98%	in stock	$228.00	$159.00

Description

• Catalog Number: AE11334
• Chemical Name: 4-Methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide
• CAS Number: 1093403-33-8
• Molecular Formula: C26H24N6O2S2
• Molecular Weight: 516.6378
• MDL Number: MFCD22572733
• SMILES: O=C(c1sc(nc1C)c1cccnc1)Nc1ccccc1c1cn2c(n1)scc2CN1CCOCC1

Computed Properties

• Complexity: 758
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 4.2

Literature

• Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.

  Inflammatory bowel diseases 20160301

• A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.

  PloS one 20150101

• Sirtuin 1 activator SRT2104 protects Huntington's disease mice.

  Annals of clinical and translational neurology 20141201

• SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass.

  Aging cell 20141001

• A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.

  British journal of clinical pharmacology 20140701